====== Exosome for Stroke ======

Currently only a very limited number of therapeutic approaches are available for treatment of [[stroke]] patients, and the vast majority of neuroprotective agents that tested positively in pre-clinical studies failed in [[clinical trial]]s. In recent years, the clinical value of the use of [[exosome]]s for stroke treatment has received widespread attention due their unique characteristics such as low [[immunogenicity]], low [[toxicity]] and biodegradability, ability to cross the[[ blood brain barrier]] (BBB), and their important role in communication between cells. More and more evidence suggests that the secretion of exosomes is the mechanism underlying the protection induced by [[mesenchymal stromal cell]]s (MSCs) after [[stroke]]. Exosomes are thought to support brain [[restoration]] and induce repairing effects, including neurovascular [[remodeling]], and anti-[[apoptosis]] and [[antiinflammatory]] effects. Recent reports have focused on the clinical application of exosomes as a potential [[drug]] delivery approach. A review of Hong et al. from [[Shanghai]] focuses on the ability of [[exosome]]s to interrupt the [[stroke-]]induced pathologic processes of stroke, and on publications describing how to achieve more effective treatment of stroke with exosomes
((Hong SB, Yang H, Manaenko A, Lu J, Mei Q, Hu Q. Potential of Exosomes for the 
Treatment of Stroke. Cell Transplant. 2018 Dec 6:963689718816990. doi:
10.1177/0963689718816990. [Epub ahead of print] PubMed PMID: 30520322.
)).